Core Viewpoint - The company, Heptagon Pharmaceuticals-B (02142.HK), has entered into a non-exclusive licensing agreement with Pfizer to advance preclinical antibody discovery for various potential disease indications [1] Group 1: Agreement Details - Heptagon's wholly-owned subsidiary, Nona Biotech (Suzhou) Co., Ltd., will provide Pfizer with global access to its proprietary HCAb platform for the development of fully human only heavy chain antibodies [1] - Nona Biotech will receive an upfront payment and is entitled to receive regulatory, clinical, and commercial milestone payments [1] - The collaboration allows Nona Biotech to utilize its HCAb platform, advanced B cell screening technology, and comprehensive services for antibody discovery, development, and engineering [1]
和铂医药-B(02142.HK)子公司与辉瑞订立非独家授权协议